Targa Therapeutics Corp. - Product Pipeline Review - H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Targa Therapeutics Corp. - Product Pipeline Review - H2 2011” provides data on the Targa Therapeutics Corp.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Targa Therapeutics Corp.’s corporate website, SEC filings, investor presentations and featured press releases, both from Targa Therapeutics Corp. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Targa Therapeutics Corp. - Product Pipeline Review - H2 2011” provides data on the Targa Therapeutics Corp.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Targa Therapeutics Corp.’s corporate website, SEC filings, investor presentations and featured press releases, both from Targa Therapeutics Corp. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Targa Therapeutics Corp. - Brief Targa Therapeutics Corp. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Targa Therapeutics Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Targa Therapeutics Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Targa Therapeutics Corp.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Targa Therapeutics Corp.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Targa Therapeutics Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Targa Therapeutics Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Targa Therapeutics Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Targa Therapeutics Corp. and identify potential opportunities in those areas.
Targa Therapeutics Corp. Snapshot
Targa Therapeutics Corp. Overview
Key Information
Key Facts
Targa Therapeutics Corp. – Research and Development Overview
Key Therapeutic Areas
Targa Therapeutics Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Targa Therapeutics Corp. – Pipeline Products Glance
Targa Therapeutics Corp. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Targa Therapeutics Corp. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Targa Therapeutics Corp. – Drug Profiles
BreMel/TNF-a
Product Description
Mechanism of Action
R&D Progress
Granzyme B/VEGF
Product Description
Mechanism of Action
R&D Progress
HuM195/rGel
Product Description
Mechanism of Action
R&D Progress
scFvMel/rGel
Product Description
Mechanism of Action
R&D Progress
VEGF/rGel
Product Description
Mechanism of Action
R&D Progress
Targa Therapeutics Corp. – Pipeline Analysis
Targa Therapeutics Corp. – Pipeline Products by Therapeutic Class
Targa Therapeutics Corp. - Pipeline Products By Target
Targa Therapeutics Corp. – Pipeline Products by Route of Administration
Targa Therapeutics Corp. – Pipeline Products by Molecule Type
Targa Therapeutics Corp. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Targa Therapeutics Corp., Deals Summary
Targa Therapeutics Corp., Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
SuperGen Terminates Licensing Agreement With Targa Therapeutics
SuperGen Enters Into Licensing Agreement With Targa Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Targa Therapeutics Corp., Key Information
Targa Therapeutics Corp., Key Facts
Targa Therapeutics Corp. – Pipeline by Therapy Area and Indication, H2 2011
Targa Therapeutics Corp. – Pipeline by Stage of Development, H2 2011
Targa Therapeutics Corp. – Monotherapy Products in Pipeline, H2 2011
Targa Therapeutics Corp. - Phase I, H2 2011
Targa Therapeutics Corp. – Pre-Clinical, H2 2011
Targa Therapeutics Corp. - Pipeline By Therapeutic Class, H2 2011
Targa Therapeutics Corp. - Pipeline By Target, H2 2011
Targa Therapeutics Corp. – Pipeline By Route of Administration, H2 2011
Targa Therapeutics Corp. – Pipeline By Molecule Type, H2 2011
Targa Therapeutics Corp., Deals Summary
SuperGen Terminates Licensing Agreement With Targa Therapeutics
SuperGen Enters Into Licensing Agreement With Targa Therapeutics
LIST OF FIGURES
Targa Therapeutics Corp. – Pipeline by Therapy Area and Indication, H2 2011
Targa Therapeutics Corp. – Pipeline by Stage of Development, H2 2011
Targa Therapeutics Corp. – Monotherapy Products in Pipeline, H2 2011
Targa Therapeutics Corp. – Pipeline By Therapeutic Class, H2 2011
Targa Therapeutics Corp. - Pipeline By Target, H2 2011
Targa Therapeutics Corp. – Pipeline By Route of Administration, H2 2011
Targa Therapeutics Corp. – Pipeline By Molecule Type, H2 2011
Targa Therapeutics Corp. Overview
Key Information
Key Facts
Targa Therapeutics Corp. – Research and Development Overview
Key Therapeutic Areas
Targa Therapeutics Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Targa Therapeutics Corp. – Pipeline Products Glance
Targa Therapeutics Corp. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Targa Therapeutics Corp. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Targa Therapeutics Corp. – Drug Profiles
BreMel/TNF-a
Product Description
Mechanism of Action
R&D Progress
Granzyme B/VEGF
Product Description
Mechanism of Action
R&D Progress
HuM195/rGel
Product Description
Mechanism of Action
R&D Progress
scFvMel/rGel
Product Description
Mechanism of Action
R&D Progress
VEGF/rGel
Product Description
Mechanism of Action
R&D Progress
Targa Therapeutics Corp. – Pipeline Analysis
Targa Therapeutics Corp. – Pipeline Products by Therapeutic Class
Targa Therapeutics Corp. - Pipeline Products By Target
Targa Therapeutics Corp. – Pipeline Products by Route of Administration
Targa Therapeutics Corp. – Pipeline Products by Molecule Type
Targa Therapeutics Corp. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Targa Therapeutics Corp., Deals Summary
Targa Therapeutics Corp., Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
SuperGen Terminates Licensing Agreement With Targa Therapeutics
SuperGen Enters Into Licensing Agreement With Targa Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Targa Therapeutics Corp., Key Information
Targa Therapeutics Corp., Key Facts
Targa Therapeutics Corp. – Pipeline by Therapy Area and Indication, H2 2011
Targa Therapeutics Corp. – Pipeline by Stage of Development, H2 2011
Targa Therapeutics Corp. – Monotherapy Products in Pipeline, H2 2011
Targa Therapeutics Corp. - Phase I, H2 2011
Targa Therapeutics Corp. – Pre-Clinical, H2 2011
Targa Therapeutics Corp. - Pipeline By Therapeutic Class, H2 2011
Targa Therapeutics Corp. - Pipeline By Target, H2 2011
Targa Therapeutics Corp. – Pipeline By Route of Administration, H2 2011
Targa Therapeutics Corp. – Pipeline By Molecule Type, H2 2011
Targa Therapeutics Corp., Deals Summary
SuperGen Terminates Licensing Agreement With Targa Therapeutics
SuperGen Enters Into Licensing Agreement With Targa Therapeutics
LIST OF FIGURES
Targa Therapeutics Corp. – Pipeline by Therapy Area and Indication, H2 2011
Targa Therapeutics Corp. – Pipeline by Stage of Development, H2 2011
Targa Therapeutics Corp. – Monotherapy Products in Pipeline, H2 2011
Targa Therapeutics Corp. – Pipeline By Therapeutic Class, H2 2011
Targa Therapeutics Corp. - Pipeline By Target, H2 2011
Targa Therapeutics Corp. – Pipeline By Route of Administration, H2 2011
Targa Therapeutics Corp. – Pipeline By Molecule Type, H2 2011